Senior health reporter Anjalee Khemlani joins Brad Smith and Madison Mills on Catalysts to take a look at pharmaceutical ...

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.

On the heels of Terns’ positive Phase I results that analysts compared with Lilly’s and Pfizer’s weight loss pills in ...

Terns Pharmaceuticals will advance TERN-601 into Phase II after early-stage data showed the oral therapy led to weight loss ...

Pfizer recently revealed Phase 2 clinical ... Patients showed 13.1% weight loss after 12 weeks on the pill, compared to 6% after 12 weeks in Wegovy's early trial. Terns showed its early-stage ...

Cancer patients with wasting syndrome have gained weight after taking Pfizer’s anti-GDF-15 antibody in a midphase study, ...

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

Pfizer recently revealed Phase 2 clinical trial data ... the company's own injectable weight-loss drug Wegovy. Patients showed 13.1% weight loss after 12 weeks on the pill, compared to 6% after 12 ...

The experimental treatment, TERN-601, is part of the second generation of weight-loss drugs, which aim to offer a more ...